An arrangement agreed between the supplier of a PBS-listed medicine and the Australian Government that adequately monitors identified risks (or undesired events such as cost-ineffective use or greater-than-expected use) and manages them by appropriate mechanisms for sharing the impact of these risks between the supplier and the government should they arise. CoA
Recently Added
- So You Want to Build Your Disease’s First Online Patient Registry: An Educational Guide
- Involve Australia – Guidelines for Community Involvement in Genomic Research
- Holiday Gift Guide 2023
- Interacting with Patient Communities: Areas for Pharmaceutical companies to consider
- PVI CaPPRE Enhancing Patient Engagement in Australia Report 2023